title: The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease.
abstract: OBJECTIVE
  To evaluate the psychometric properties and patterns of decline on the total score and item scores of the cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) in patients with Alzheimer Disease (AD).
  
  
  METHODS
  We analyzed data from 536 AD outpatients randomized to the placebo group in two identical 26-week multicenter drug trials.
  
  
  RESULTS
  Mean deterioration at week 26 on the ADAS-Cog total score for subjects with moderate dementia was 84% greater than that for those with milder severity ( p < 0.001). After adjusting for this effect, age ( p = 0.015) and educational level ( p = 0.01) also predicted cognitive decline. In a model, absolute change for most individual ADAS items was less than 10% of the possible change, and it was generally smaller than one-third of the standard deviation of the measure. Measurement error variability was greatest for word recognition and the "placebo" effect was greatest for word recall. Variability increased with trial duration in a model.
  
  
  CONCLUSIONS
  There is a relationship between baseline severity and magnitude of cognitive decline. In 6-month trials, measurement error makes a substantial contribution to the variance in ADAS-Cog change scores. Sensitivity to intervention effects will therefore depend both on the variability and magnitude of change. Such data must be considered when designing future trials to minimize measurement error variability and increase sensitivity for specific populations.
authors.affiliation: Duke University Medical Center, Durham, North Carolina 27710, USA. murali@acpub.duke.edu
authors.forename: P M
authors.initials: PM
authors.lastname: Doraiswamy
authors.forename: L
authors.initials: L
authors.lastname: Kaiser
authors.forename: F
authors.initials: F
authors.lastname: Bieber
authors.forename: R L
authors.initials: RL
authors.lastname: Garman
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D003072:Cognition Disorders / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008609:Mental Status Schedule / Q000706:statistics & numerical data; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009483:Neuropsychological Tests / Q000706:statistics & numerical data*; D018697:Nootropic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015990:Placebo Effect; D011594:Psychometrics; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results
chemical_list: D018697:Nootropic Agents